phenylephrine
≈ 10 min read
Names in other languages
- Englishphenylephrine
- Françaisphényléphrine
- EspañolFenilefrina
- Polskifenylefryna
- Portuguêsfenilefrina
- Русскийфенилэфрин
- СрпскиФенилефрин
- СрпскиFenilefrin
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Phenylephrine, sold under the brand names Neosynephrine and Sudafed PE among others, is a medication used as a decongestant for uncomplicated nasal congestion in the form of a nasal spray or oral tablet, intravenously in cases of low blood pressure, or as a suppository to relieve hemorrhoids. It can also be applied to the skin. Common side effects when taken by mouth or injected include nausea, vomiting, headache, and anxiety. Use on hemorrhoids is generally well tolerated. Severe side effects may include a slow heart rate, intestinal ischemia, chest pain, kidney failure, and tissue death at the site of injection. It is unclear whether its use during pregnancy and breastfeeding is safe. Phenylephrine is a selective α 1 -adrenergic receptor agonist with minimal to no β-adrenergic receptor agonist activity or induction of norepinephrine release. It causes constriction of both arteries and veins. Phenylephrine was patented in 1933 and came into medical use in 1938. It is available as a generic medication. Unlike pseudoephedrine, abuse of phenylephrine is very uncommon. Its effectiveness as an oral nasal decongestant has been questioned. In 2023, a U.S. Food and Drug Administration (FDA) panel concluded that the drug was ineffective as a nasal decongestant when taken orally, performing no better than placebo.…
Phenylephrine, sold under the brand names Neosynephrine and Sudafed PE among others, is a medication used as a decongestant for uncomplicated nasal congestion in the form of a nasal spray or oral tablet, intravenously in cases of low blood pressure, or as a suppository to relieve hemorrhoids. It can also be applied to the skin. Common side effects when taken by mouth or injected include nausea, vomiting, headache, and anxiety. Use on hemorrhoids is generally well tolerated. Severe side effects may include a slow heart rate, intestinal ischemia, chest pain, kidney failure, and tissue death at the site of injection. It is unclear whether its use during pregnancy and breastfeeding is safe. Phenylephrine is a selective α 1 -adrenergic receptor agonist with minimal to no β-adrenergic receptor agonist activity or induction of norepinephrine release. It causes constriction of both arteries and veins. Phenylephrine was patented in 1933 and came into medical use in 1938. It is available as a generic medication. Unlike pseudoephedrine, abuse of phenylephrine is very uncommon. Its effectiveness as an oral nasal decongestant has been questioned. In 2023, a U.S. Food and Drug Administration (FDA) panel concluded that the drug was ineffective as a nasal decongestant when taken orally, performing no better than placebo. In November 2024, the FDA proposed to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the temporary relief of nasal congestion.
Other uses
Phenylephrine has been used in the treatment of postural orthostatic tachycardia syndrome (POTS). It has been found to improve vascular resistance, enhance circulatory support, and improve symptoms of orthostatic intolerance in people with the condition. It has been described as particularly effective in people with neuropathic POTS. However, phenylephrine has not been specifically approved for the treatment of POTS, and data on this use are limited. This is also the case with other medications used in the treatment of POTS. Phenylephrine has been used in the treatment of priapism. It is also sometimes used as a reversal medication of Trimix injections.
Available forms
Phenylephrine is available in the form of oral tablets and syrups for use as a nasal decongestant, as an intravenous solution to treat hypotension, as an ophthalmic solution, spray, or eye drop to cause pupil dilation, and as a cocoa butter suppository, among other forms. It was also previously available as a metered aerosol for inhalation, but this formulation was discontinued. Phenylephrine is available both alone and in combination with other drugs. These other drugs include antihistamines like chlorpheniramine, doxylamine, promethazine, and mepyramine (pyrilamine); analgesics like paracetamol (acetaminophen), ibuprofen, ketorolac, and codeine; cough suppressants like dextromethorphan; expectorants like guaifenesin; anticholinergics like cyclopentolate and tropicamide; and β-adrenergic receptor agonists like isoprenaline (isoproterenol). It is used in combination with antihistamines and analgesics in cough and cold preparations, with anticholinergics in ophthalmic formulations, and with β-adrenergic receptor agonists in inhalational forms. Intravenous phenylephrine is always formulated by itself.
Contraindications
Phenylephrine is contraindicated in people with hypertension, hyperthyroidism, and heart disease due to its vasoconstrictor effects. Relative contraindications include people with Raynaud's syndrome due to vasoconstriction, those taking monoamine oxidase inhibitors (MAOIs) due to inhibition of the metabolism of phenylephrine, and people with prostate problems due to potential exacerbation of urinary retention.
Others
Prostatic hyperplasia can also be worsened by use, and chronic use can lead to rebound hyperemia. People with a history of anxiety or panic disorders, or on anticonvulsant medication for epilepsy, should not take this substance. The drug interaction might produce seizures. Some patients have been shown to have an upset stomach, severe abdominal cramping, and vomiting issues connected to taking this drug. Phenylephrine is pregnancy category C. Due to the lack of studies done in animals and humans, it is unknown whether there is harm to the fetus. Phenylephrine should only be given to pregnant women who have a clear need. Extended use may cause rhinitis medicamentosa, a condition of rebound nasal congestion.
Pharmacokinetics
Absorption
Phenylephrine is rapidly absorbed from the gastrointestinal tract when taken orally. However, its absorption is incomplete and erratic. Because of extensive first-pass metabolism, phenylephrine has an oral bioavailability of only about 38% relative to intravenous administration. However, another source has stated that the bioavailability of phenylephrine is poorly documented and may actually be as low as 0.003%. The time to peak concentrations is 1.0 to 1.3 hours.
Distribution
The steady-state volume of distribution of phenylephrine is 340 L. Phenylephrine does not cross the blood–brain barrier and hence is a peripherally selective drug with no central nervous system activity. Its lack of blood-brain barrier permeability is related to its hydroxyl groups and high hydrophilicity. The lack of central permeation with phenylephrine is in contrast to certain other related decongestant and sympathomimetic agents like pseudoephedrine, ephedrine, and phenylpropanolamine.
Metabolism
Phenylephrine is metabolized in the intestines and liver prior to reaching the systemic circulation when taken orally. It is extensively metabolized during first-pass metabolism due to susceptibility to monoamine oxidases, similarly to epinephrine. Phenylephrine is metabolized via oxidative deamination by both MAO-A and MAO-B. In contrast to epinephrine and norepinephrine, phenylephrine is not a catecholamine, and is not metabolized by catechol O-methyltransferase (COMT). Besides monoamine oxidase, phenylephrine is also metabolized by sulfation and glucuronidation conjugation. Non-oral routes of phenylephrine, like intranasal, ophthalmic, and parenteral, do not undergo first-pass metabolism in the gastrointestinal tract. The major metabolite of phenylephrine is meta-hydroxymandelic acid, which is inactive. Lesser metabolites of phenylephrine include sulfate and glucuronide conjugates, which are also inactive. Unlike phenylephrine, related sympathomimetics with a methyl group at the α carbon (i.e., amphetamines), like ephedrine, pseudoephedrine, phenylpropanolamine, methoxamine, and methoxyphenamine, are resistant to degradation by monoamine oxidase.
Elimination
Phenylephrine is primarily excreted in urine. It is recovered 86% in urine. The drug is excreted in urine 3 to 16% unchanged, 57% as meta-hydroxymandelic acid, and 8% as sulfate conjugates. Glucuronide conjugates constitute a smaller portion of phenylephrine. Phenylephrine has a relatively short elimination half-life of 2.0 to 3.0 hours regardless of route of administration. Its lack of metabolism by COMT is said to be responsible for its much longer duration of action than related agents like norepinephrine.
Chemistry
Phenylephrine is a substituted phenethylamine and can also be referred to structurally as (R)-β,3-dihydroxy-N-methylphenethylamine. It is closely structurally related to epinephrine (adrenaline; 3,4,β-trihydroxy-N-methylphenethylamine), differing from it only in the absence of one hydroxyl group on the phenyl ring. It is a chiral compound and is used as the enantiopure (R)-stereoisomer. The racemic form has not been formally named or used. Phenylephrine is the N-methylated derivative of norfenefrine (3,β-dihydroxyphenethylamine). The racemic N-ethyl analogue is etilefrine (ethylphenephrine). Synephrine (p-synephrine, oxedrine; 4,β-dihydroxyphenethylamine) is a positional isomer of phenylephrine. In contrast to epinephrine and norepinephrine (noradrenaline; 3,4,β-trihydroxyphenethylamine), phenylephrine is not a catecholamine since it does not have two hydroxyl groups on its phenyl ring. Besides the catecholamines, the chemical structure of phenylephrine somewhat resembles that of amphetamine (α-methylphenethylamine). However, phenylephrine does not have a methyl group at the α carbon and hence is not an amphetamine itself. Phenylephrine is a small-molecule compound with the molecular formula C 9 H 13 NO 2 and a molecular weight of 167.205 g/mol. It is a highly hydrophilic compound, with an experimental log P of -0.3. Phenylephrine is used medically almost always as the hydrochloride salt. However, the free base form and the tannate salt have also been used pharmaceutically to a much lesser extent. Pivenfrine is the 3-pivalate ester of phenylephrine and has much greater lipophilicity in comparison.
History
Phenylephrine was first patented in 1927 and was first introduced for medical use in 1938.
Society and culture
Names
Phenylephrine is the generic name of the drug and its , , and , while its and in the case of the hydrochloride salt are phenylephrine hydrochloride. Synonyms of phenylephrine include phenephrine, fenefrine, L -m-synephrine, metaoxedrine, neo-oxedrine, mesatonum, neosynephrine, and m-sympatol. Brand names of phenylephrine include Neosynephrine or Neo-Synephrine and Sudafed PE, among numerous others. It is sometimes referred to as simply "neo," an abbreviation of the trade name Neo-Synephrine, especially in critical care settings.
Availability
Phenylephrine is available worldwide as a prescription drug in many different formulations.
Research
Hair loss
Topical phenylephrine has been studied in the treatment of alopecia (hair loss). It has been found to cause contraction of arrector pili muscles (hair erector muscles), thereby increasing the force required to pluck hair and reducing hair shedding during brushing. A topical combination of phenylephrine, synephrine, and tyramine, with the code name DA-007, is under formal development for the treatment of alopecia.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378630754 under CC BY-SA 4.0; modifications have been made.